Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data

The Lancet Public Health

Volumn 2, Issue 9, 2017, Pages e411-e419

  Attaei, Marjan W ^a   Khatib, Rasha ^b   McKee, Martin ^c   Lear, Scott ^d   Dagenais, Gilles ^e   Igumbor, Ehimario U ^f   AlHabib, Khalid F ^g   Kaur, Manmeet ^h   Kruger, Lanthe ⁱ   Teo, Koon ^j   Lanas, Fernando ^k   Yusoff, Khalid ^l,m   Oguz, Aytekin ⁿ   Gupta, Rajeev ^o   Yusufali, Afzalhussein M ^p   Bahonar, Ahmad ^q   Kutty, Raman ^r   Rosengren, Annika ^s   Mohan, Viswanathan ^t   Avezum, Alvaro ^u   Yusuf, Rita ^v   Szuba, Andrzej ^w   Rangarajan, Sumathy ^j   Chow, Clara ^x   Yusuf, Salim ^j   O'Donnell, M ^y   Mente, A ^y   Leong, D ^y   Smyth, A ^y   Joseph, P ^y   Islam, S ^y   Zhang, M ^y   Hu, W ^y   Ramasundarahettige, C ^y   Wong, G ^y   Dayal, L ^y   Casanova, A ^y   Dehghan, M ^y   Lewis, G ^y   Aliberti, A ^y   Reyes, A ^y   Zaki, A ^y   Lewis, B ^y   Zhang, B ^y   Agapay, D ^y   Hari, D ^y   Milazzo, E ^y   Ramezani, E ^y   Hussain, F ^y   Shifaly, F ^y   Kay, I ^y   Rimac, J ^y   Swallow, J ^y   Heldman, L ^y   more..

^a MCMASTER UNIVERSITY   (Canada)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d SIMON FRASER UNIVERSITY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^g KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^h POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

ⁱ NORTH WEST UNIVERSITY   (South Africa)

^j HAMILTON HEALTH SCIENCES   (Canada)

^k UNIVERSIDAD DE LA FRONTERA   (Chile)

^l UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^m UCSI UNIVERSITY   (Malaysia)

ⁿ ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^o Department of Preventive Cardiology and Internal Medicine   (India)

^p DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^q ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^r GOVERNMENT MEDICAL COLLEGE   (India)

^s UNIVERSITY OF GOTHENBURG   (Sweden)

^t MADRAS DIABETES RESEARCH FOUNDATION   (India)

^u INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^v INDEPENDENT UNIVERSITY   (Bangladesh)

^w WROCLAW MEDICAL UNIVERSITY   (Poland)

^x UNIVERSITY OF SYDNEY   (Australia)

^y a)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DRUG INDUSTRY; ECONOMIC ASPECT; EDUCATIONAL STATUS; FEMALE; FOOD; GENDER; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HIGH INCOME COUNTRY; HOUSEHOLD INCOME; HOUSING; HUMAN; HYPERTENSION; LOW INCOME COUNTRY; MALE; MIDDLE INCOME COUNTRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOCIOECONOMICS; TRAFFIC AND TRANSPORT; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ECONOMICS; INCOME; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HUMANS; HYPERTENSION; INCOME; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85028775982     PISSN: None     EISSN: 24682667     Source Type: Journal    
DOI: 10.1016/S2468-2667(17)30141-X     Document Type: Article

References (36)

1. Olsen, MH, Angell, SY, Asma, S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 388 (2016), 2665–2712.
2. Messerli, FH, Williams, B, Ritz, E, Essential hypertension. Lancet 370 (2007), 591–603.
3. Chow, KC, Teo, KK, Rangarajan, S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
4. Cushman, WC, Ford, CE, Cutler, JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 4 (2002), 393–404.
5. James, PA, Oparil, S, Carter, BL, et al. Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
6. WHO. The selection of essential drugs. http://apps.who.int/medicinedocs/documents/s20185en/s20185en.pdf, 1977 (accessed Sept 20, 2016).
7. Gress, TW, Nieto, FJ, Shahar, E, Wofford, MR, Brancati, FL, Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342 (2000), 905–912.
8. Mancia, G, The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 42 (2005), 17–25.
9. Lonn, EM, Bosch, J, Lopez-Jaramillo, P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
10. Yusuf, S, Bosch, J, Dagenais, G, et al. Cholestrol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
11. Teo, K, Chow, CK, Vaz, M, Rangarajan, S, Yusuf, S, PURE Investigators–Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 158 (2009), 1–7.e1.
12. Corsi, DJ, Subramanian, S V, Chow, CK, et al. Prospective Urban Rural Epidemiology (PURE) study: baseline characteristics of the household sample and comparative analyses with national data in 17 countries. Am Heart J, 166, 2013, 636 46.e4.
13. Yusuf, S, Islam, S, Chow, CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378 (2011), 1231–1243.
14. Yusuf, S, Rangarajan, S, Teo, K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 371 (2014), 818–827.
15. Khatib, R, McKee, M, Shannon, H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016), 61–69.
16. Chow, CK, Lock, K, Madhavan, M, et al. Environmental profile of a community's health (EPOCH): an instrument to measure environmental determinants of cardiovascular health in five countries. PLoS One 5 (2010), 1–8.
17. Corsi, DJ, Subramanian, SV, McKee, M, et al. Environmental Profile of a Community's Health (EPOCH): an ecometric assessment of measures of the community environment based on individual perception. PLoS One, 7, 2012, e44410.
18. Sowers, JR, Epstein, M, Frohlich, ED, Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37 (2001), 1053–1059.
19. Xu, K, Evans, DB, Kawabata, K, Zeramdini, R, Klavus, J, Murray, CJL, Household catastrophic health expenditure: a multicountry analysis. Lancet 362 (2003), 111–117.
20. The World Bank. Inflation, consumer prices (annual %). http://data.worldbank.org/indicator/FP.CPI.TOTL.ZG (accessed Aug 1, 2016).
21. The World Bank. PPP conversion factor, private consumption (LCU per international $). http://data.worldbank.org/indicator/PA.NUS.PPP (accessed Aug 1, 2016).
22. Jarari, N, Rao, N, Peela, JR, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens, 22, 2015, 7.
23. Doshi, JA, Zhu, J, Lee, BY, Kimmel, SE, Volpp, KG, Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 119 (2009), 390–397.
24. Viswanathan, M, Golin, CE, Jones, CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States. Ann Intern Med 157 (2012), 785–795.
25. Dinarvand, R, New national drug policy in iran leading to expanded pharmaceutical market and extended access of public to medicines. Iran J Public Health 38 (2009), 158–161.
26. Lim, SS, Gaziano, TA, Gakidou, E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370 (2007), 2054–2062.
27. WHO. Scaling up action against noncommunicable diseases: how much will it cost?. http://whqlibdoc.who.int/publications/2011/9789241502313_eng.pdf, 2011 (accessed Sept 20, 2016).
28. Cameron, A, Ewen, M, Ross-Degnan, D, Ball, D, Laing, R, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373 (2009), 240–249.
29. van Mourik, MSM, Cameron, A, Ewen, M, Laing, RO, Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 10 (2010), 1–9.
30. Mendis, S, Fukino, K, Cameron, A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 85 (2007), 279–288.
31. Khatib, R, Schwalm, J, Yusuf, S, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One 9 (2014), 1–12.
32. Risso-Gill, I, Balabanova, D, Majid, F, et al. Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach. BMC Health Serv Res, 15, 2015, 254.
33. Legido-Quigley, H, Lopez, PAC, Balabanova, D, et al. Patients' knowledge, attitudes, behaviour and health care experiences on the prevention, detection, management and control of hypertension in Colombia: a qualitative study. PLoS One 10 (2015), 1–16.
34. Wirtz, VJ, Hogerzeil, H V, Gray, AL, et al. Essential medicines for universal health coverage. Lancet 389 (2017), 403–476.
35. UN. Transforming our world: the 2030 agenda for sustainable development. https://sustainabledevelopment.un.org/content/documents/21252030%20Agenda%20for%20Sustainable%20Development%20web.pdf, 2015 (accessed Dec 27, 2016).
36. Yusuf, S, Lonn, E, Pais, P, et al. Blood-pressure and cholestrol lowering in persons without cardiovascular disease. N Engl J Med 374 (2016), 2032–2043.